Stock RO ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

News Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Real-time Estimate Cboe Europe
Other stock markets
 04:49:14 2024-04-23 am EDT 		5-day change 1st Jan Change
247 CHF +1.15% Intraday chart for Roche Holding AG +3.87% -5.51%
Apr. 19 Swiss Equities Flash Green; Middle East Tensions Rise MT
Apr. 19 Roche: approval in lung cancer in the United States CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Swiss Equities Flash Green; Middle East Tensions Rise
MT
Roche: approval in lung cancer in the United States
CF
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine
MT
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval
DJ
Roche's Early-stage Lung Cancer Treatment Alecensa Wins US FDA Nod
MT
FDA Approves Roche?s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer
CI
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
BU
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment
DJ
ROCHE HOLDINGS AG : UBS sticks Neutral
ZD
Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial
MT
Roche: positive phase III results in MS
CF
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
BU
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)
CI
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating
ZD
Roche: positive phase III data in lymphoma
CF
Roche's Late-stage Trial for Columvi Antibody Meets Primary Survival Endpoint in B-cell Lymphoma
MT
Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
DJ
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
BU
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating
ZD
Swiss Market Index Falls as ECB Signals June Rate Cut
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RO Stock
  5. News Roche Holding AG